Effect of tocilizumab treatment for COVID-19-induced acute respiratory distress syndrome (ARDS) on renal function of patients
Tropical Journal of Pharmaceutical Research
; 21(3):629-634, 2022.
Article
in English
| CAB Abstracts | ID: covidwho-1789575
ABSTRACT
Purpose:
To study the effect of tocilizumab (TCZ) on the renal function of patients with severe coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS).
Pharmacology [VV730]; Prion, Viral, Bacterial and Fungal Pathogens of Humans [VV210]; Pesticides and Drugs; Control [HH405]; Non-communicable Human Diseases and Injuries [VV600]; acute respiratory distress syndrome; adverse effects; blood; coronavirus disease 2019; creatinine; drug therapy; glomerular filtration rate; glomerulus; human diseases; kidney diseases; kidneys; lungs; men; monoclonal antibodies; mortality; nitrogen; renal failure; renal function; respiratory diseases; therapy; tocilizumab; treatment outcomes; urea; viral diseases; women; man; Severe acute respiratory syndrome coronavirus 2; Turkey; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Mediterranean Region; OECD Countries; upper-middle income countries; very high Human Development Index countries; West Asia; Asia; adverse reactions; chemotherapy; kidney disorders; nephropathy; renal diseases; death rate; kidney failure; kidney function; lung diseases; SARS-CoV-2; therapeutics; viral infections
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Type of study:
Experimental Studies
Language:
English
Journal:
Tropical Journal of Pharmaceutical Research
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS